NGT: Europe's parliament greenlights gene-edited crops
The Strasbourg vote authorizes new genomic techniques in EU agriculture — but buries the patent question, a slow-burning threat to thousands of small farmers.
The European Parliament’s final vote on June 17 approved a regulation that clears a path for gene-edited crops — while quietly abandoning the patent ban and mandatory labeling its own members had voted for just eighteen months earlier. The real stakes: who controls Europe’s seeds in twenty years.
At a Glance
On June 17, 2026, the European Parliament, the EU’s directly elected legislative body, voted by a comfortable majority in favor of a regulation authorizing new genomic techniques (NGTs) in agriculture, removing a category of these plants from the bloc’s existing GMO framework.
A December 2025 trilateral negotiating deal abandoned the patent ban and mandatory consumer labeling that the Parliament itself had approved in 2024 — replacing both with a voluntary code of conduct.
The deepest fault line is not environmental but economic: who will sell seeds to European farmers in twenty years, and at what price?
This image is used for illustrative purposes only.
A vote foretold — and what it traded away
The outcome was never really in doubt. By midday Wednesday in Strasbourg, members of the European Parliament voted by a comfortable majority to adopt the regulation on new genomic techniques (NGTs) for agriculture. All amendments that would have reopened negotiations were rejected.
NGTs — primarily CRISPR-based molecular editing tools — allow scientists to modify a plant’s own genome without inserting foreign DNA from another species, as first-generation GMOs do. The potential applications include drought-resistant varieties, disease-resistant crops, and plants that require fewer pesticides. Wheat with lower gluten content. Bananas resistant to black sigatoka fungus, which is devastating plantations across the Caribbean.
Yet since a July 2018 ruling by the Court of Justice of the European Union (CJEU), the EU’s highest court for legal interpretation, NGT plants had been legally classified as GMOs — and therefore subject to the same strict authorization and labeling requirements. The regulation adopted Wednesday carves a significant exemption from that framework.
The text creates two categories. Category 1 covers NGT plants with a limited number of modifications, deemed equivalent to varieties achievable through conventional breeding: no GMO authorization process, and no consumer-facing label on the final product — only a mention on seed bags sold to farmers. Category 2 plants, with more complex modifications, remain under the full GMO regulatory regime. Both categories are banned from organic farming. NGT varieties engineered for herbicide tolerance or insecticide production cannot be marketed.
The regulation does not take effect immediately. It will require formal adoption by the EU Council of member states, followed by publication in the Official Journal of the European Union — a process that typically runs several months. Actual market entry for NGT products is not expected before 2027 at the earliest.
What the trilogue deal actually cost
Wednesday’s vote was not the beginning of this story. Reading its final chapter against the earlier ones makes clear what shifted — and who benefited.
On February 7, 2024, the Parliament’s environment committee voted for a full ban on patents covering NGT plants, their derived seeds, and the processes used to produce them. It also voted for mandatory labeling all the way to the consumer. The reasoning was explicit: if a plant can be patented, it is not truly equivalent to a conventional variety. On April 24, 2024, the full Parliament confirmed that position, 307 to 263, with 41 abstentions.
Four rounds of trilogue negotiations — the closed-door process through which the European Commission, the EU Council of member states, and Parliament representatives hammer out final legislation — ran from May to December 2025. The fourth session, on December 3, 2025, produced an agreement. The patent ban was dropped. Mandatory consumer labeling for Category 1 products was dropped. In their place: an expert group, a voluntary industry code of conduct on patent transparency and licensing, and a requirement for companies registering an NGT plant to declare all existing or pending patents. The European Commission also committed to publishing an impact assessment within one year of the first NGT products reaching market, covering seed availability, innovation, and sector competitiveness.
The regulation’s lead rapporteur, Swedish MEP Jessica Polfjärd of the center-right European People’s Party (EPP), argued that the technology would help Europe grow climate-resistant crops with higher yields on less land. French centrist MEP Pascal Canfin contended the vote had established a distinctly European model for new genomic techniques — one that he insisted was not an import of U.S. or Brazilian approaches.
Analysis: the question this regulation does not resolve
Opposition to the text arrived from multiple directions. Environmental organizations such as Pollinis raised the alarm over the absence of consumer labeling for Category 1 products: if no indication appears on a supermarket shelf, how does informed choice function?
The agricultural divide is sharper. France’s Confédération paysanne, the country’s third-largest farmers’ union, brought roughly sixty farmers to the steps of the European Parliament in Strasbourg on Tuesday, June 16. Thomas Gibert, a market gardener from the Haute-Vienne region and the union’s spokesperson, described the NGT regulation as carrying a “major risk of privatization of life itself and homogenization of crops.” [translated from French] Socialist French MEP Christophe Clergeau, whose amendments targeting the patent provisions were rejected Wednesday, warned that the entire network of small European seed producers could gradually be displaced by large multinationals holding costly patent portfolios.
On the other side, Copa-Cogeca, the umbrella organization representing Europe’s main agricultural unions, welcomed the regulation as a measure that would open up innovation for European farmers. The European Food Safety Authority (EFSA), the EU’s independent food risk assessment body, expressed support for the approach adopted. France’s national food safety agency (ANSES) was more cautious — calling for case-by-case evaluation and a broader democratic debate before any large-scale deployment.
That gap — EFSA endorsing the framework, ANSES urging restraint — illustrates a structural tension in European scientific governance: the distance between EU-level harmonized risk assessment and national precautionary preferences, particularly in a country where public skepticism toward GMOs has historically run high.
The deeper question this regulation does not answer is economic. If patents on NGT plants remain in place — even softened by a voluntary code of conduct — and if only major international seed companies can finance the research needed to bring NGT varieties to market, then Europe’s agricultural innovation could, over the next decade, become dependent on decisions made in corporate boardrooms outside the EU rather than in Brussels. That risk of seed market concentration is not resolved by Wednesday’s vote. It has been deferred — to an impact study the Commission has promised to deliver after the first commercial products arrive on shelves.
The question that will define whether this vote ages well is not whether CRISPR-edited wheat is safe to eat. It is whether the farmer who grows it will still have a choice of whose seeds to buy.
The Bottom Line
Europe made a calculated bet: that genomic innovation will serve its farmers better than regulatory caution would protect them. That bet may prove right on drought-resistant varieties and disease-resistant crops. But it rests on assumptions that the voluntary patent code will hold against industrial pressure, that the Commission’s impact study will arrive before market positions are locked in, and that small seed producers will retain meaningful access to innovation that large competitors will help fund and patent.
→ For a detailed account of how the 2025 trilogue negotiations dismantled the Parliament’s earlier positions on patents and labeling, read our full analysis: EU’s gene-editing vote: how a patent deal was negotiated away in Europe’s food future
Sources: France Info · AFP · Vert · Agri Mutuel · European Parliament · EFSA · In the French News